Neurosarkoidose

Zusammenfassung

Neurosarkoidose ist die seltene Manifestation der granulomatösen Multisystemerkrankung Sarkoidose im zentralen oder peripheren Nervensystem. Die Ätiologie ist ungeklärt, vermutete Auslöser sind infektiösen Agentien und Umwelttoxine. Das histopathologische Korrelat besteht aus nicht-verkäsenden epitheloidzelligen Granulomen mit geordneten Riesenzellen vom Langhans-Typ und einem peripheren Lymphozytenwall. Die klinische Präsentation ist variabel und manifestiert sich im zentralen und peripheren Nervensystem. Ausfällen der kranialen Hirnnerven, aseptischen Meningitiden, raumfordernden Parenchymläsionen im ZNS mit Störung des neuroendokrinologischen Systems oder Krampfanfällen sind bekannt. Periphere Neuropathien, insbesondere Small-Fiber-Neuropathien und Myopathien kommen vor. 1/3 zeigt mehr als eine neurologische Manifestation. Die Diagnose ist eine Herausforderung und Sicherheit ist nur mittels positiver Biopsie des Nervensystems möglich. Da eine Biopsie nicht immer durchführbar ist, kann der Verdacht auf Neurosarkoidose bei suggestiven klinischen/paraklinischen Befunden gestellt werden. Neurosarkoidose kann nur dann diagnostiziert wird, wenn mögliche Differenzialdiagnosen ausgeschlossen wurden. Jede symptomatische Neurosarkoidose sollte immunsupprimierend therapiert werden – für asymptomatische Krankheitsverläufe liegen keine Empfehlungen vor. Therapiestudien liegen nicht vor, dennoch besteht Konsens darüber, primär Kortikosteroide anzuwenden. Bei unzureichendem Ansprechen oder schwerwiegenden Symptomen ist eine Eskalation auf Immunsuppressiva empfohlen. Neuerdings können auch Therapieempfehlungen für neutralisierende Antikörper gegen TNF-α bei therapierefraktären Verläufen abgeleitet werden. Diese Therapien werden empfohlen und werden aufgrund guter Wirksamkeit bei günstigen Nebenwirkungsprofilen zunehmend an Bedeutung gewinnen. Die Prognose hängt vom Manifestationsort ab, ein isolierter Hirnnervenbefall ist günstig, Parenchymläsionen können komplizierte Verläufe nehmen. Bei 2/3 verläuft die Neurosarkoidose monophasisch mit Remission. Bei dem Rest sind schubförmige oder progrediente Verläufe möglich, mit einer Letalität von ca. 10%.

Abstract

Neurosarcoidosis is a rare manifestation of the granulomatous multisystem disease, sarcoidosis, in the central/peripheral nervous systems. Its aetiology is not clear, possible triggers are infectious agents and environmental toxins. The histopathologogical correlate is non-caseating epitheliod-cell granuloma with ordered giant cells of Langhans type and peripheral lymophocyte wall. The clinical presentation is variable. Defects of cranial nerves, aseptic meningitis, space-filling parenchymal lesions in the CNS with disorders of the neuroendocrine system or seizures are common. Peripheral neuropathies, especially small-fibre neuropathies, and myopathies can occur. 1/3 exhibit more than one manifestation. The diagnosis is a challenge and a clear result requires a positive biopsy of the nervous system. Since biopsies are not always possible the suspicion of neurosarcoidosis is based on suggestive clinical/paraclinical findings. The diagnosis is only made when all possible differential diagnoses have been excluded. Symptomatic neurosarcoidosis calls for immunosuppressive therapy – there are no clear recommendations for asymptomatic courses. Studies are not available but there is consensus for the primary use of corticosteroids. In cases of inadequate response or severe symptoms escalation to immunosuppressants is recommended. Recent cases recommend neutralising antibodies against TNF-α for therapy-resistant courses. These new therapies are important due to their good efficacy and favourable side effect profiles. The prognosis depends on the site of manifestation with an isolated cranial nerve attack being more favourable while parenchymal lesions take a complicated course. In 2/3 neurosarcoidosis is monophasic with complete remission. In the rest, episodic or progressive courses occur with a lethality of approx. 10%.

Schlüsselwörter

Sarkoidose - Granulome - TNF-alpha-Antagonisten - entzündliche ZNS-Erkrankung

Keywords

sarcoidosis - granulomas - TNF-α antagonists - inflammatory CNS diseases

• Literatur

• 1 Young RC, Rachal RE, Cowan CL. Sarcoidosis--the beginning: historical highlights of personalities and their accomplishments during the early years. J Natl Med Assoc 1984; 76: 887-896
• 2 Krumholz A, Stern BJ. Neurosarkoidose. Handb Clin Neurol 2014; 119: 305-333
• 3 Colover J. Sarcoidosis with involvement of the nervous system. Brain 1948; 71: 451-475
• 4 Rybicki BA, Major M, Popovich J et al. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol 1997; 145: 234-241
• 5 Weinberg S, Bennett H, Weinstock I. Central nervous system manifestations of sarcoidosis in children. Case report and review. Clin Pediatr (Phila) 1983; 22: 477-481
• 6 Rybicki BA, Iannuzzi MC, Frederick MM et al. Familial aggregation of sarcoidosis. A case-control etiologic study of sarcoidosis (ACCESS). Am J Respir Crit Care Med 2001; 164: 2085-2091
• 7 Sverrild A, Backer V, Kyvik KO et al. Heredity in sarcoidosis: a registry-based twin study. Thorax 2008; 63: 894-896
• 8 Demirkok SS, Basaranoglu M, Coker E et al. Seasonality of the onset of symptoms, tuberculin test anergy and Kveim positive reaction in a large cohort of patients with sarcoidosis. Respirology 2007; 12: 591-593
• 9 Iwai K, Takemura T, Kitaichi M et al. Pathological studies on sarcoidosis autopsy. II. Early change, mode of progression and death pattern. Acta Pathol Jpn 1993; 43: 377-385
• 10 Scola RH, Werneck LC, Prevedello DM et al. Symptomatic muscle involvement in neurosarcoidosis: a clinicopathological study of 5 cases. Arq Neuropsiquiatr 2001; 59: 347-352
• 11 Stjernberg N, Cajander S, Truedsson H et al. Muscle involvement in sarcoidosis. Acta Med Scand 1981; 209: 213-216
• 12 Nowak DA, Widenka DC. Neurosarcoidosis: a review of its intracranial manifestation. J Neurol 2001; 248: 363-372
• 13 Saboor SA, Johnson NM, McFadden J. Detection of mycobacterial DNA in sarcoidosis and tuberculosis with polymerase chain reaction. Lancet 1992; 339: 1012-1015
• 14 Eishi Y, Suga M, Ishige I et al. Quantitative analysis of mycobacterial and propionibacterial DNA in lymph nodes of Japanese and European patients with sarcoidosis. J Clin Microbiol 2002; 40: 198-204
• 15 Song Z, Marzilli L, Greenlee BM et al. Mycobacterial catalase-peroxidase is a tissue antigen and target of the adaptive immune response in systemic sarcoidosis. J Exp Med 2005; 201: 755-767
• 16 Dubaniewicz A, Kämpfer S, Singh M. Serum anti-mycobacterial heat shock proteins antibodies in sarcoidosis and tuberculosis. Tuberculosis 2006; 86: 60-67
• 17 Hajizadeh R, Sato H, Carlisle J et al. Mycobacterium tuberculosis Antigen 85 A Induces Th-1 Immune Responses in Systemic Sarcoidosis. J Clin Immunol 2007; 27: 445-454
• 18 McCaskill JG, Chason KD, Hua X et al. Pulmonary Immune Responses to Propionibacterium acnesin C57BL/6 and BALB/c Mice. Am J Respir Cell Mol Biol 2006; 35: 347-356
• 19 Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med 2007; 357: 2153-2165
• 20 Izbicki G, Chavko R, Banauch GI et al. World Trade Center „sarcoid-like“ granulomatous pulmonary disease in New York City Fire Department rescue workers. Chest 2007; 131: 1414-1423
• 21 Newman LS, Rose CS, Bresnitz EA et al. A Case Control Etiologic Study of Sarcoidosis. Am J Respir Crit Care Med 2004; 170: 1324-1330
• 22 Brewerton DA, Cockburn C, James DC et al. HLA antigens in sarcoidosis. Clin Exp Immunol 1977; 27: 227-229
• 23 Iannuzzi MC, Maliarik MJ, Poisson LM et al. Sarcoidosis susceptibility and resistance HLA-DQB1 alleles in African Americans. Am J Respir Cri Care Med 2003; 167: 1225-1231
• 24 Valeyre D, Prasse A, Nunes H et al. Sarcoidosis. Lancet 2014; 383: 1155-1167
• 25 Valentonyte R, Hampe J, Huse K et al. Sarcoidosis is associated with a truncating splice site mutation in BTNL2. Nat Genet 2005; 37: 357-364
• 26 Iannuzzi MC, Rybicki BA. Genetics of sarcoidosis: candidate genes and genome scans. Proc Am Thorac Soc 2007; 4: 108-116
• 27 Agostini C, Adami F, Semenzato G. New pathogenetic insights into the sarcoid granuloma. Curr Opin Rheumatol 2000; 12: 71-76
• 28 Steffen M, Petersen J, Oldigs M et al. Increased secretion of tumor necrosis factor-alpha, interleukin-1-beta, and interleukin-6 by alveolar macrophages from patients with sarcoidosis. J Allergy Clin Immunol 1993; 91: 939-949
• 29 Gilbert S, Steinbrech DS, Landas SK et al. Amounts of angiotensin-converting enzyme mRNA reflect the burden of granulomas in granulomatous lung disease. Am Rev Respir Dis 1993; 148: 483-486
• 30 Pueringer RJ, Schwartz DA, Dayton CS et al. The relationship between alveolar macrophage TNF, IL-1, and PGE2 release, alveolitis, and disease severity in sarcoidosis. Chest 1993; 103: 832-838
• 31 Miyara M, Amoura Z, Parizot C et al. The immune paradox of sarcoidosis and regulatory T cells. J Exp Med 2006; 203: 359-370
• 32 Rappl G, Pabst S, Riemann D et al. Regulatory T cells with reduced repressor capacities are extensively amplified in pulmonary sarcoid lesions and sustain granuloma formation. Clin Immunol 2011; 140: 71-83
• 33 Hunninghake GW, Crystal RG. Mechanisms of hypergammaglobulinemia in pulmonary sarcoidosis. Site of increased antibody production and role of T lymphocytes. J Clin Invest 1981; 67: 86-92
• 34 Zajicek JP, Scolding NJ, Foster O et al. Central nervous system sarcoidosis–diagnosis and management. QJM 1999; 92: 103-117
• 35 Pawate S, Moses H, Sriram S. Presentations and outcomes of neurosarcoidosis: a study of 54 cases. QJM 2009; 102: 449-460
• 36 Stern BJ, Krumholz A, Johns C et al. Sarcoidosis and its neurological manifestations. Arch Neurol 1985; 42: 909-917
• 37 Hoitsma E, Faber CG, Drent M et al. Neurosarcoidosis: a clinical dilemma. Lancet Neurol 2004; 3: 397-407
• 38 Joseph FG, Scolding NJ. Sarcoidosis of the nervous system. Pract Neurol 2007; 7: 234-244
• 39 Langrand C, Bihan H, Raverot G et al. Hypothalamo-pituitary sarcoidosis: a multicenter study of 24 patients. QJM 2012; 105: 981-995
• 40 Sohn M, Culver DA, Judson MA et al. Spinal cord neurosarcoidosis. Am J Med Sci 2014; 347: 195-198
• 41 Rieger J, Hosten N. Spinal cord sarcoidosis. Neuroradiology 1994; 36: 627-628
• 42 Junger SS, Stern BJ, Levine SR et al. Intramedullary spinal sarcoidosis: clinical and magnetic resonance imaging characteristics. Neurology 1993; 43: 333-337
• 43 Wegener S, Linnebank M, Martin R et al. Clinically isolated neurosarcoidosis: a recommended diagnostic path. Eur Neurol 2014; 73: 71-77
• 44 Hoitsma E, Marziniak M, Faber CG et al. Small fibre neuropathy in sarcoidosis. Lancet 2002; 359: 2085-2086
• 45 Friese MA. Neurosarkoidose. In: Brandt T, Gerloff C, Diener HC. Hrsg Therapie und Verlauf neurologischer Erkrankungen. 6. Auflage: Stuttgart: W. Kohlhammer; 2012: 531-538
• 46 Terushkin V, Stern BJ, Judson MA et al. Neurosarcoidosis. Neurologist 2010; 16: 2-15
• 47 Berger C, Sommer C, Meinck H-M. Isolated sarcoid myopathy. Muscle Nerve 2002; 26: 553-56
• 48 Fayad F, Lioté F, Berenbaum F et al. Muscle involvement in sarcoidosis: a retrospective and followup studies. J Rheumatol 2006; 33: 98-103
• 49 Pickuth D, Heywang-Köbrunner SH. Neurosarcoidosis: evaluation with MRI. J Neuroradiol 2000; 27: 185-88
• 50 Fels C, Riegel A, Javaheripour-Otto K et al. Neurosarcoidosis: findings in MRI. Clin Imaging 2004; 28: 166-169
• 51 Petereit H-F, Reske D, Tumani H et al. Soluble CSF interleukin 2 receptor as indicator of neurosarcoidosis. J Neurol 2010; 257: 1855-1863
• 52 Linnebank M, Kesper K, Jeub M et al. Hereditary elevation of angiotensin converting enzyme suggesting neurosarcoidosis. Neurology 2003; 61: 1819-1820
• 53 Sharma P, Smith I, Maguire G et al. Clinical value of ACE genotyping in diagnosis of sarcoidosis. Lancet 1997; 349: 1602-1603
• 54 Marangoni S, Argentiero V, Tavolato B. Neurosarcoidosis. J Neurol 2005; 253: 488-495
• 55 Wengert O, Rothenfusser-Korber E, Vollrath B et al. Neurosarcoidosis: correlation of cerebrospinal fluid findings with diffuse leptomeningeal gadolinium enhancement on MRI and clinical disease activity. J Neurol Sci 2013; 335: 124-130
• 56 Wong SH, Jenkinson MD, Faragher B et al. Brain biopsy in the management of neurology patients. Eur Neurol 2010; 64: 42-45
• 57 Heckmann JG, Stefan H, Heuss D et al. Isolated muscular sarcoidosis. Eur J Neurol 2001; 8: 365-366
• 58 Maeshima S, Koike H, Noda S et al. Clinicopathological features of sarcoidosis manifesting as generalized chronic myopathy. J Neurol 2015; epub ahead of print
• 59 Themistocleous AC, Ramirez JD, Serra J et al. The clinical approach to small fibre neuropathy and painful channelopathy. Pract Neurol 2014; 14: 368-379
• 60 Winterbauer RH, Lammert J, Selland M et al. Bronchoalveolar lavage cell populations in the diagnosis of sarcoidosis. Chest 1993; 104: 352-361
• 61 Hoitsma E, Drent M, Sharma OP. A pragmatic approach to diagnosing and treating neurosarcoidosis in the 21st century. Curr Opin Pulm Med 2010; 16: 472-479
• 62 Bargagli E, Bianchi N, Margollicci M et al. Chitotriosidase and soluble IL-2 receptor: Comparison of two markers of sarcoidosis severity. Scand J Clin Lab Invest 2008; 68: 479-483
• 63 Bargagli E, Maggiorelli C, Rottoli P. Human chitotriosidase: a potential new marker of sarcoidosis severity. Respiration 2008; 76: 234-238
• 64 Teirstein AS, Machac J, Almeida O et al. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest 2007; 132: 1949-1953
• 65 Sobic-Saranovic D, Artiko V, Obradovic V. FDG PET Imaging in Sarcoidosis. Sem Nucl Med 2013; 43: 404-411
• 66 Bartels S, Kyavar L, Blumstein N et al. FDG PET findings leading to diagnosis of neurosarcoidosis. Clin Neurol Neurosurg 2013; 115: 85-88
• 67 Promteangtrong C, Salavati A, Cheng G et al. The role of positron emission tomography-computed tomography/magnetic resonance imaging in the management of sarcoidosis patients. Hell J Nucl Med 2014; 17: 123-135
• 68 Gonzalez-Granado LI. Reply: Presentations and outcomes of neurosarcoidosis: a study of 54 cases. QJM 2009; 102: 889-889
• 69 Stern BJ. Neurological complications of sarcoidosis. Curr Opin Neurol 2004; 17: 311-316
• 70 Sharma OP. Vitamin D, calcium, and sarcoidosis. Chest 1996; 109: 535-539
• 71 Lower EE, Broderick JP, Brott TG et al. Diagnosis and management of neurological sarcoidosis. Arch Intern Med 1997; 157: 1864-1868
• 72 Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis 2000; 17: 60-66
• 73 Dewit O, Moreels T, Baert F et al. Limitations of extensive TPMT genotyping in the management of azathioprine-induced myelosuppression in IBD patients. Clin Biochem 2011; 44: 1062-1066
• 74 Chaussenot A, Bourg V, Chanalet S et al. [Neurosarcoidosis treated with mycophenolate mofetil: two cases]. Rev Neurol (Paris) 2007; 163: 471-475
• 75 Sharma OP. Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurological involvement. Arch Neurol 1998; 55: 1248-1254
• 76 Antoniu SA. Infliximab for the therapy of chronic sarcoidosis. Expert Opin Investig Drugs 2007; 16: 753-756
• 77 Rossman MD, Newman LS, Baughman RP et al. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23: 201-208
• 78 Sodhi M, Pearson K, White ES et al. Infliximab therapy rescues cyclophosphamide failure in severe central nervous system sarcoidosis. Respir Med 2009; 103: 268-273
• 79 Marnane M, Lynch T, Scott J et al. Steroid-unresponsive neurosarcoidosis successfully treated with adalimumab. J Neurol 2009; 256: 139-140
• 80 Bomprezzi R, Pati S, Chansakul C et al. A case of neurosarcoidosis successfully treated with rituximab. Neurology 2010; 75: 568-570
• 81 Ferriby D, de Seze J, Stojkovic T et al. Long-term follow-up of neurosarcoidosis. Neurology 2001; 57: 927-929
• 82 Sato H, Grutters JC, Pantelidis P et al. HLA-DQB1*0201. Am J Respir Cell Mol Biol 2002; 27: 406-412
• 83 Lockstone HE, Sanderson S, Kulakova N et al. Gene Set Analysis of Lung Samples Provides Insight into Pathogenesis of Progressive, Fibrotic Pulmonary Sarcoidosis. Am J Respir Crit Care Med 2010; 181: 1367-1375
• 84 Jamilloux Y, Néel A, Lecouffe-Desprets M. A et al. Progressive multifocal leukoencephalopathy in patients with sarcoidosis. Neurology 2014; 82: 1307-1313
• 85 Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 2010; 9: 425-437
• 86 Christoforidis GA, Spickler EM, Recio MV et al. MR of CNS sarcoidosis: correlation of imaging features to clinical symptoms and response to treatment. AJNR Am J Neuroradiol 1999; 20: 655-669
• 87 Lexa FJ, Grossman RI. MR of sarcoidosis in the head and spine: spectrum of manifestations and radiographic response to steroid therapy. AJNR Am J Neuroradiol 1994; 15: 973-982
• 88 Seltzer S, Mark AS, Atlas SW. CNS sarcoidosis: evaluation with contrast-enhanced MR imaging. AJNR Am J Neuroradiol 1991; 12: 1227-1233